Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$1.14
-4.2%
$0.99
$0.62
$7.50
$22.10M0.771.85 million shs149,870 shs
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
$9.30
-5.0%
$4.12
$2.86
$79.00
$9.37M2.48381,613 shs374,175 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.46
+0.6%
$3.12
$2.57
$6.88
$21.37M0.639,040 shs778 shs
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
$2.08
-9.2%
$2.01
$0.12
$10.00
$19.12MN/A625,604 shs52,493 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
0.00%+5.56%+8.57%+5.56%+131.90%
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
0.00%+64.60%+173.53%+86.90%-25.57%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+1.59%+4.82%-1.17%-47.43%
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
0.00%-0.95%-2.80%-41.41%+207,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioVie Inc. stock logo
BIVI
BioVie
2.4346 of 5 stars
3.83.00.00.02.70.00.6
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
3.5733 of 5 stars
3.55.00.00.02.50.00.0
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.7573 of 5 stars
0.03.00.00.02.01.70.6
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
3.8968 of 5 stars
3.80.00.00.03.33.31.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
3.50
Strong Buy$3.00163.16% Upside
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
3.00
Buy$57.50518.28% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
3.50
Strong Buy$10.00380.77% Upside

Current Analyst Ratings Breakdown

Latest KZIA, NAII, BIVI, and SNYR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
3/18/2025
BioVie Inc. stock logo
BIVI
BioVie
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$2.54 per shareN/A
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
$2.31M4.06N/AN/A($1.97) per share-4.72
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.17N/AN/A$12.77 per share0.27
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
$33.59M0.57N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$32.12M-$7.91N/AN/AN/A-134.07%-93.44%8/21/2025 (Estimated)
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
-$17.56MN/A0.00N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.26%-9.36%-4.82%N/A
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
N/AN/A0.003.53N/AN/AN/AN/AN/A

Latest KZIA, NAII, BIVI, and SNYR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
$0.07$0.10+$0.03$0.10$9.03 million$8.17 million
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q3 2025
BioVie Inc. stock logo
BIVI
BioVie
-$0.32-$0.15+$0.17-$0.15N/AN/A
3/31/2025Q4 2024
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
$0.10$0.01-$0.09$0.01$10.55 million$10.30 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
16.94
16.94
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
N/A
0.24
0.24
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
1018.57 million17.71 millionNo Data
Kazia Therapeutics Limited stock logo
KZIA
Kazia Therapeutics
121.01 million4.99 millionOptionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.90 millionNot Optionable
Synergy CHC Corp. (Uplisting) stock logo
SNYR
Synergy CHC Corp. (Uplisting)
409.19 millionN/AN/A

Recent News About These Companies

Synergy CHC Announces 7th Quarter of Profitability

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioVie stock logo

BioVie NASDAQ:BIVI

$1.14 -0.05 (-4.20%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$1.15 +0.01 (+0.53%)
As of 06/13/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Kazia Therapeutics stock logo

Kazia Therapeutics NASDAQ:KZIA

$9.30 -0.49 (-5.01%)
Closing price 06/13/2025 04:00 PM Eastern
Extended Trading
$9.40 +0.09 (+1.02%)
As of 06/13/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.46 +0.02 (+0.55%)
Closing price 06/13/2025 03:50 PM Eastern
Extended Trading
$3.46 0.00 (0.00%)
As of 06/13/2025 06:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Synergy CHC Corp. (Uplisting) stock logo

Synergy CHC Corp. (Uplisting) NASDAQ:SNYR

$2.08 -0.21 (-9.17%)
As of 06/13/2025 04:00 PM Eastern

Synergy CHC Corp. engages in the marketing and distribution of branded health and wellness products. The company was founded on December 29, 2010 and is headquartered in Westbrook, ME.